The mTOR Kinase Inhibitor CZ415 Inhibits Human Papillary Thyroid Carcinoma Cell Growth | Zendy

Xiaobin Li | Zendy; Zongze Li | Zendy; Yimin Song | Zendy; Wenjing Liu | Zendy; Ziwen Liu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The mTOR Kinase Inhibitor CZ415 Inhibits Human Papillary Thyroid Carcinoma Cell Growth

Author(s) -

Xiaobin Li,

Zongze Li,

Yimin Song,

Wenjing Liu,

Ziwen Liu

Publication year - 2018

Publication title -

cellular physiology and biochemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.486

H-Index - 87

eISSN - 1421-9778

pISSN - 1015-8987

DOI - 10.1159/000488625

Subject(s) - thyroid carcinoma , cancer research , pi3k/akt/mtor pathway , medicine , cell growth , discovery and development of mtor inhibitors , thyroid , kinase , protein kinase a , carcinoma , endocrinology , oncology , biology , signal transduction , microbiology and biotechnology , biochemistry

Mammalian target of rapamycin (mTOR) plays an important role in papillary thyroid carcinoma (PTC) cell progression. CZ415 is a novel, highly-efficient and specific mTOR kinase inhibitor. The current study tested the potential anti-tumor activity of CZ415 in human PTC cells.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research